NCT05888961 · RECRUITING
Single-center Prospective Longitudinal Study of Taste in Patients With Cognitive Disorders at Different Stages of Severity (Isolated Cognitive Complaint, Minor or Major Neurocognitive Alzheimer-type Disorders) by Analysis of Gustatory Evoked Potentials
This study looks at how sense of taste changes across stages of memory decline. Researchers compare healthy people with those who have memory complaints, mild impairment, or mild-to-moderate Alzheimer's-type dementia. They use taste tests, scalp electrodes, blood tests, and body measurements. It is an observational study, so nothing is being tested as a treatment.
You may qualify if
- Person who has given oral consent.
- For patients with mild to moderate Alzheimer\'s disease, the primary caregiver and the patient will be asked to provide oral consent
- Person of legal age
- Body Mass Index (BMI) \< 30 kg/m².
- For the healthy group: absence of cognitive complaints and normal neurological assessment
- Patients meeting the criteria for isolated cognitive complaint: presence of cognitive complaint but normal neuropsychological evaluation
- Patients meeting diagnostic criteria for minor cognitive impairment: imaging (brain MRI) and neuropsychological assessment with a Clinical Dementia Rating (CDR) score of 0.5
- Patients meeting diagnostic criteria for mild to moderate Alzheimer\'s disease: imaging (brain MRI), neuropsychobiological criteria (consultation with neuropsychological assessment, CSF biomarkers), MMSE score ≥ 20 and CDR score of 1 or 1.5
- Fasting for at least 2 hours before GEP measurement
You're excluded if
- MMSE score\<15
- Known COVID-19 infection within 6 months prior to inclusion
- Person not affiliated to national health insurance system
- Person under a legal protection measure (curatorship, guardianship)
- Person subject to a measure of legal protection
- Pregnant, parturient or breastfeeding women
- Subjects with a pacemaker (contraindication to bioelectrical impedance measurement)
- Adult unable to express consent or to perform cognitive tests.
- Active smoker (> 4 cigarettes per day on a regular basis)
- Diabetic subject (type 1 or type 2)
- Subject with acute or chronic ENT disease
- Treatment interfering with gustation
- Brain MRI showing another cause of neurocognitive disorder (except for vascular lesions Fazekas 1 accepted)
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-09-25